Peplin trading halted
Tuesday, 05 October, 2004
Brisbane based Peplin Biotech (ASX:PEP) has called a halt to trading shares on the ASX for at least a week, telling shareholders to expect a major announcement.
The company told the ASX that its managing director Michael Aldridge was travelling overseas to conduct "important negotiations" in relation to the company's anti-cancer products, and expected to be able to either make a price sensitive announcement or reconsider the trading halt in one week.
Peplin was recently granted a broad US patent covering lead drug PEP005 and related compounds for anti-cancer applications over and above its existing patents covering the compound as a treatment for skin cancer. The latter is the subject of a US$23 million collaboration and licence agreement with Allergan, and the drug is currently in Phase I/II clinical trials.
Before the halt was called, the company's shares were trading at AUD$0.71.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
